Statins: new drugs for treating osteoporosis?

Bibliography

• WHITFIELD JF, MORLEY P, WILLICK G: The parathyroid hormone, its fragments and analogs-potent bone-builders for treating osteoporosis. Exp. Opin. Invest. Drugs (2000) 9:1293–1315.
   PubMed Web of Science ®Google Scholar
• MUNDY G, GARRETT R, HARRIS S et al.: Stimulation of bone formation in vitro and in rodents by statins. Science (1999) 286:1946–1949.
   PubMed Web of Science ®Google Scholar
• GARRETT IR, GUTIERREZ G, MUNDY GR: Statins and bone formation. Curr. Pharma. Design (2001) (In press).
   Google Scholar
• MUNDY G: Pathogenesis of osteoporosis and challenges for drug delivery. Adv. Drug Del. Rev. (2000) 42:165–173.
   PubMed Web of Science ®Google Scholar
• JI X, CHEN D, XU C et al.: Patterns of gene expression associated with BMP-2-induced osteoblasts and adipocyte differentiation of mesenchymal progenitor cell 3T3-F442A. J. Bone Miner. Res. (2000) 15:132–139.
   Google Scholar
• YAMAGUCHI A, KOMORI T, SUDA T: Regulation of osteoblast differentiation mediated by bone morpho-genetic proteins, hedgehogs and Cbfal. Endocrine Revs. (2000) 21:393–411.
   PubMed Web of Science ®Google Scholar
• GHOSH-CHOUDHURY N, WINDLE JJ, KOOP BA et al.: Immortalized murine osteoblasts derived from BMP 2-T-antigen expressing transgenic mice. Endocrinology (1996) 137:331–339.
   PubMed Web of Science ®Google Scholar
• SUGIYAMA M, KODAMA T, KONISHI K et al.: Compactin and simvastatin, but not pravastatin, induce bone morphogenic protein-2 in human osteosarcoma cells. Biochem. Biophys. Res. Commun. 2000 271:688–692.
   PubMed Web of Science ®Google Scholar
• DOWNS JR, CLEARFIELD M, WETS S et al.: Primary prevention of acute coronary events with lovastatin in men and with average cholesterol levels: results of AFCAPS/Tex CAPS: Air Force/Texas Coronary Athersclerosis Prevention Study. JAMA (1998) 279 :1615–1622.
   PubMed Web of Science ®Google Scholar
• ESSIG M, VRTOVSNIK F, FRIEDLANDER G: Lesinhibiteurs de PHMG CoAreductase: nouveaux modes d'action, nouvelles indications? Thérapie (2000) 55:43–49.
   PubMedGoogle Scholar
• LAROSA JC, HE J, VUPPUTURI S: Effects of statins on riskof coronary disease: a meta-analysis of randomized controlled trials. JAMA (1999) 282:2340–2346.
   PubMed Web of Science ®Google Scholar
• MOHLER ER, DELANTY N, RADER DJ et al.: Statins andcerebrovascular disease: plaque attack to prevent brain attack. Vasc. Med. (1999) 4:269–272.
   PubMed Web of Science ®Google Scholar
• SHEPHERD J: lipid lowering: statins and the future.Heart (2000) 84:46–47.
   PubMed Web of Science ®Google Scholar
• SHEPHERD J, COBBE SM, FORD I et al.: Prevention ofcoronary heart disease with pravastatin in men with hypercholesterolemia. N. Engl. J. Med. (1995) 333:1301–1307.
   PubMed Web of Science ®Google Scholar
• GUTIERREZ G, GARRETT JR, ROSSINI G et al: Dermalapplication of lovastatin to rats causes greater increases in bone formation and plasma concentra-tion than when administered by oral gavage. j Bone Miner. Res. (2000) 15:S427 (Abstract).
   Google Scholar
• WHANG K, ZHAO M, QIAO M et al.: Administration oflovaststin locally in low doses in a novel delivery system induces prolonged bone formation. J Bone Miner. Res. (2000) 15:S225.
   Web of Science ®Google Scholar
• BELLOSTA S, FERRI N, BERNINI F et al.: Non-lipid-relatedeffects of statins. Ann. Med. (2000) 32:164–176.
   PubMed Web of Science ®Google Scholar
• ELSON CE, PEFFLEY DM, HENTOSH P et al.: Isoprenoid-mediated inhibition of mevalonate synthesis: potential application to cancer. Proc. Soc. Exp. Biol. Med. (1999) 221:294–311.
   PubMed Web of Science ®Google Scholar
• NEWMAN TB, HULLEY SB: Carcinogenicity of lipid-lowering drugs. JAMA (1996) 275:55–60.
   PubMed Web of Science ®Google Scholar
• GARRETT IR, GUTIERREZ G, CHEN D et al.: Specific inhibitors of the chymotryptic component of the proteasome are potent bone anabolic agents. J. Bone Miner. Res. (2000) 15:S197 (Abstract).
   Google Scholar
• FUJITA T, FUKUYAMA R, IZUMO N et al.: Enhanced Cbfaltransactivation as a basic mechanism to trigger bone anabolic action of PTH(1–34). J. Bone Miner. Res. (2000) 15:S373 (Abstract).
   Google Scholar
• MOORE TL, KRISHNAN VG, ONYIA JE et al.: Amechanismfor bone anabolic activity of 1311–1 through Cbfal /Osf-2. J. Bone Miner. Res. (2000) 15:S158 (Abstract).
   Google Scholar
• BAUER DC, MUNDY GR, JAMAL SA et al.: Statin use, bone mass and fracture: an analysis of two prospective studies. J. Bone. Miner. Res. (1999) 14:S179.
   Web of Science ®Google Scholar
• CHAN K, ANDRADE SE, BOLES M et al.: Inhibitors of hydroxymethylglutaryl-coenzyme A reductase and risk of fracture among older women. Lancet (2000) 355:2185–2188.
   PubMed Web of Science ®Google Scholar
• METER CR, SCHLIENGER RC, KRAENZLIN ME et al.: HMG-CoA reductase inhibitors and the risk of fractures. JAMA (2000) 283:3205–3210.
   PubMed Web of Science ®Google Scholar
• DOUGLAS LO: Is exposure to HMG-CoA reductase inhibitors (statins), fibrates, or other lipid-powering drugs associated with reduced risk of bone fracture in older patients. J Fain. Pract. (2000) 49:849–450.
   PubMedGoogle Scholar
• WANG PS, SOLOMON DH, MOGUN H et al.: HMG-CoA reductase inhibitors and the risk of hip fractures in elderly patients. JAMA (2000) 283:3211–3216.
   PubMed Web of Science ®Google Scholar
• CHUNG YS, LEE MD, LEE SK et al.: IIMG-CoA reductase inhibitors increase BMD in Type 2 diabetes mellitus patients. J. Clin. Endocrinol Metab. (2000) 85:1137–1142.
   PubMed Web of Science ®Google Scholar
• LACROIX AZ, CAULEY JA, JACKSON R et al: Does statin use reduce the risk of fracture in postmenopausal women? Results from the Women's Health Initiative Observational Study (WHI-OS). J. Bone Miner. Res. (2000) 15:S155 (Abstract).
   Google Scholar
• VAN STAA TP, WEGMAN SLJ, DEVRIES F et al.: The use of statins and risk of fractures. J. Bone Miner. Res. (2000) 15:S155 (Abstract).
   Google Scholar
• CAULEY JA, JACKSON R, PETTINGER M et al.: Statin use and bone mineral density (BMD) in older women: The Women's Health Initiative Observational Study (WI II-0S). J. Bone Miner. Res. (2000) 15:S155 (Abstract).
   Google Scholar
• KUREISHI Y, LUO Z, SHIOJIMA I et al.: The IIMG-CoA reductase inhibitor simvaststin activates the protein kinase Akt and promotes angiogenesis in normocho-lesterolemic animals. Nature Med. (2000) 6:1004–1010.
   PubMed Web of Science ®Google Scholar
• LAUFS U, GERTZ K, HUANG P et al.: Atorvastatin upregu-lates Type III nitric oxide synthase in thrombocytes decreases platelet activation and protects from cerebral ischemia in normocholesterolemic mice. Stroke (2000) 31:2442–2449.
   PubMed Web of Science ®Google Scholar